• KRAS-mutant colorectal cancers show variable response to RAS inhibitors

    Preclinical research found that KRAS-mutant colorectal cancer models respond differently to RAS(ON) inhibitor RMC-7977 based on PI3K signaling and cyclin D1 expression patterns, with combined RAS and PI3K inhibition showing synergistic effects in some tumors. (Cell Reports)